Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Pain 3Neoplasms 2Cancer Pain 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Has results × Tapentadol × Clear all
NCT00472303 2019-11-04

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Completed
622 enrolled 31 charts

Cancer Pain, Neoplasms, Pain

NCT01165281 2017-07-21

A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

Janssen Research & Development, LLC

Phase 3 Completed
343 enrolled 15 charts

Pain

NCT00805142 2013-07-29

Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants

Janssen Pharmaceutical K.K.

Phase 2 Completed
78 enrolled 16 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡